NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, announced that a Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from local agency ACOREP to initiate the trial and has appointed Professor Patrick Katoto as principal investigator. Preparatory work, including staff training, is underway, and the NV-387 drug product is already available in the DRC, with the first patient dosing anticipated within a few weeks, barring outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. The company believes that oral delivery could offer significant advantages in resource-limited outbreak settings compared with treatments requiring infusions, which are often impractical in remote areas. Om Sai Clinical Research Private Limited is serving as the contract research organization (CRO) for this Phase II trial, as well as for the company’s planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC.
The approval marks a critical step forward in addressing Ebola outbreaks in Africa, where rapid deployment of treatments is essential. The DRC has experienced multiple Ebola outbreaks, and the availability of an oral treatment could greatly enhance the ability to contain future epidemics. The company’s move to conduct the trial in the DRC also demonstrates a commitment to testing the drug in the most affected regions, which may accelerate regulatory approvals in other countries.
NanoViricides’ platform technology is based on nanomedicine, and the company holds a worldwide exclusive perpetual license to this technology for several drugs targeting specific viruses, including Ebola and Marburg viruses. The company is also developing NV-387 for other indications such as RSV, COVID-19, influenza, and Mpox, highlighting its broad-spectrum potential. If successful, the Ebola trial could validate the nanoviricide approach and pave the way for further clinical development across multiple viral threats.
The initiation of this trial is a significant milestone for NanoViricides, as it transitions from preclinical studies to human trials. The company has been focused on advancing NV-387 into Phase II human clinical trials, and this Ebola trial represents a key component of that strategy. The outcome of the trial could have profound implications for pandemic preparedness, especially in regions where access to intravenous treatments is limited.
However, as with any drug development, there are risks. The company notes that the path to typical drug development is extremely lengthy and requires substantial capital. There can be no assurance that NV-387 will demonstrate sufficient effectiveness and safety in clinical trials. Nevertheless, the initiation of this trial is a promising development for the fight against Ebola and other viral diseases.
